Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 11:00 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2329–2352 of 4,225 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Injectable Placebo Clear all

Conditions: Prostate Cancer
Interventions: OnabotulinumtoxinA (BOTOX®), Normal Saline Placebo; Drug · Other
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 45 Years to 80 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Coronavirus, Covid19
Interventions: bamlanivimab 7000mg, BRII-196+BRII-198, AZD7442 (IV), AZD7442 (IM), SNG001, Camostat, BMS-986414 + BMS-986413, SAB-185 (3,840 Units/kg), SAB-185 (10,240 Units/kg), CASIRIVIMAB + IMDEVIMAB, Placebo for Bamlanivimab 7000mg, Placebo for Bamlanivimab 700mg, Placebo for BRII-196+BRII-198, Placebo for SNG001, Placebo for Camostat, Placebo for SAB-185 (low dose), Placebo for BMS-986414 + BMS-986413, Placebo for AZD7442 (IV), Placebo for AZD7442 (IM), Placebo for SAB-185 (high dose), bamlanivimab 700mg; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 4,044 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 207
States / cities: Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 143 more

Conditions: Healthy Volunteer
Interventions: MT1013; Drug
Lead sponsor: Shaanxi Micot Pharmaceutical Technology Co., Ltd.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Cypress, California

Conditions: Coronavirus, Coronavirus Infection, Coronavirus as the Cause of Diseases Classified Elsewhere
Interventions: BCG Vaccine, Placebo Vaccine; Biological
Lead sponsor: Texas A&M University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 659 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 6
States / cities: Los Angeles, California • Bryan, Texas • Houston, Texas

Conditions: Dermatitis, Atopic
Interventions: Dupilumab, Matching placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 6 Months to 5 Years
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 33
States / cities: Birmingham, Alabama • Gilbert, Arizona • Long Beach, California + 30 more

Conditions: Peripheral Arterial Disease
Interventions: JVS-100, Placebo; Biological
Lead sponsor: Juventas Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 24
States / cities: Birmingham, Alabama • Davis, California • Los Angeles, California + 18 more

Conditions: Healthy Volunteers, Dyslipidaemia
Interventions: NNC0491-6075, Placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 106 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Cypress, California

Conditions: Osteoporosis, Postmenopausal Osteoporosis
Interventions: Placebo, BA058 80 mcg, teriparatide; Drug
Lead sponsor: Radius Health, Inc.; Industry
Eligibility: 50 Years to 85 Years · Female only
Enrollment: 2,463 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 5
States / cities: Lakewood, Colorado • Miami, Florida • North Miami, Florida + 2 more

Conditions: COVID-19
Interventions: Peginterferon Lambda-1a, Placebo; Drug · Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Stanford, California

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: GA Depot, Placebo; Drug · Other
Lead sponsor: Mapi Pharma Ltd.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 1,016 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 11
States / cities: Birmingham, Alabama • Cullman, Alabama • Pasadena, California + 8 more

Conditions: Asthma
Interventions: Semaglutide Pen Injector 2.4mg weekly, Placebo; Drug · Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Visceral Leishmaniasis, Chagas Disease
Interventions: LXE408, Placebo, Iohexol; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Pain, Postoperative, Premature Infant, Opioid Use
Interventions: Acetaminophen, Saline; Drug
Lead sponsor: St. Louis University; Other
Eligibility: Up to 1 Month
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Alpha1-Antitrypsin Deficiency
Interventions: Fazirsiran Injection, Placebo; Drug · Other
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 37
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 28 more

Conditions: Asthma
Interventions: Benralizumab, Placebo; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 19
States / cities: Birmingham, Alabama • Los Angeles, California • Jacksonville, Florida + 16 more

Conditions: Hallux Abducto Valgus
Interventions: Botulinum toxin type A, Placebo; Biological · Drug
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years and older
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 29
States / cities: Jonesboro, Arkansas • Little Rock, Arkansas • Castro Valley, California + 25 more

Conditions: Herpes Zoster
Interventions: HZ Vaccine (IN001), Placebo, Shingrix; Biological
Lead sponsor: Shenzhen Shenxin Biotechnology Co., Ltd; Industry
Eligibility: 50 Years to 69 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Hollywood, Florida

Conditions: Diabetic Foot, Peripheral Arterial Disease
Interventions: PDA-002, Placebo; Drug
Lead sponsor: Celularity Incorporated; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Dermatitis, Atopic
Interventions: GSK1070806, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 17
States / cities: Phoenix, Arizona • North Little Rock, Arkansas • Canoga Park, California + 13 more

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Dimethyl Fumarate, Peginterferon Beta-1a, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Raleigh, North Carolina

Conditions: Polycythemia Vera
Interventions: Rusfertide, Placebo; Drug
Lead sponsor: Protagonist Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 293 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 80
States / cities: Mobile, Alabama • Glendale, Arizona • Duarte, California + 66 more

Conditions: Growth Hormone Deficiency
Interventions: VRS-317; Drug
Lead sponsor: Versartis Inc.; Industry
Eligibility: 25 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Alzheimer Dementia
Interventions: Brain Magnetic Resonance Imaging (MRI), F-18 Florbetapir Positron Emission Tomography (PET) Imaging, F-18 AV-1451 Positron Emission Tomography (PET) Imaging, Neuropsychological Testing; Diagnostic Test · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 49 Years to 72 Years · Female only
Enrollment: 299 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 6
States / cities: Phoenix, Arizona • San Francisco, California • New Haven, Connecticut + 3 more

Conditions: Anorexia Nervosa
Interventions: RM-131, Placebo; Drug
Lead sponsor: Motus Therapeutics, Inc.; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

Neoadjuvant Intraprostatic OnabotulinumtoxinA Before Radical Prostatectomy for High-Risk Localized Prostate Cancer

ACTIV-2: A Study for Outpatients With COVID-19

MT1013 Clinical TRIAL In Healthy Subject

BCG Vaccine for Health Care Workers as Defense Against COVID 19

Safety, Pharmacokinetics and Efficacy of Dupilumab in Patients ≥6 Months to <6 Years With Moderate-to-Severe Atopic Dermatitis (Liberty AD PRESCHOOL)

SDF1 Plasmid Treatment for Patients With Peripheral Artery Disease

A Study to Look at How Safe a New Medicine (NNC0491-6075) is in Healthy People and in Participants With High Levels of Fat in the Blood

Study to Evaluate the Safety and Efficacy of BA058 (Abaloparatide) for Prevention of Fracture in Postmenopausal Women

Single-Blind Study of a Single Dose of Peginterferon Lambda-1a Compared With Placebo in Outpatients With Mild COVID-19

A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS

Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Adult, Obesity-related, Symptomatic Asthma (GATA-3)

A First-in-human, Safety, Tolerability, and Pharmacokinetics Study of LXE408 in Healthy Subjects

Postoperative Pain Control & Relief in Neonates

Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein

Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics

Dysport in Hallux Abducto Valgus (HAV) Phase IIa

A Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants

Hemodynamic Effects of Intramuscular PDA-002 in Subjects Who Have Diabetic Foot Ulcer With Peripheral Arterial Disease

A Dose Finding Study to Investigate the Safety and Effectiveness of GSK1070806 in Adult Participants With Moderate to Severe Atopic Dermatitis

Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants

A Study of Rusfertide in Adults With Polycythemia Vera (PV)

VRS-317 in Adult Subjects With Growth Hormone Deficiency

Continuation of The Kronos Early Estrogen Prevention Study (KEEPS)

Phase 2 Pilot Study to Evaluate the Safety and Efficacy of RM-131 Administered to Females With Anorexia Nervosa